biostudies-literatureUnknown16(3)Oblitas CM<h4>Background</h4>This study aimed to validate the role of the D-dimer to lymphocyte ratio (DLR) for mortality prediction in a large national cohort of hospitalized coronavirus disease 2019 (COVID-19) patients.<h4>Methods</h4>A retrospective, multicenter, observational study that included hospitalized patients due to SARS-CoV-2 infection in Spain was conducted from March 2020 to March 2022. All biomarkers and laboratory indices analyzed were measured once at admission.<h4>Results</h4>A total of 10,575 COVID-19 patients were included in this study. The mean age of participants was 66.9 (±16) years, and 58.6% (6202 patients) of them were male. The overall mortality rate was 16.3% (<i>n</i> = 1726 patients). Intensive care unit admission was needed in 10.5% (<i>n</i> = 1106 patients), non-invasive mechanical ventilation was required in 8.8% (<i>n</i> = 923 patients), and orotracheal intubation was required in 7.5% (789 patients). DLR presented a c-statistic of 0.69 (95% CI, 0.68-0.71) for in-hospital mortality with an optimal cut-off above 1. Multivariate analysis showed an independent association for in-hospital mortality for DLR > 1 (adjusted OR 2.09, 95% CI 1.09-4.04; <i>p</i> = 0.03); in the same way, survival analysis showed a higher mortality risk for DLR > 1 (HR 2.24; 95% CI 2.03-2.47; <i>p</i> < 0.01). Further, no other laboratory indices showed an independent association for mortality in multivariate analysis.<h4>Conclusions</h4>This study confirmed the usefulness of DLR as a prognostic biomarker for mortality associated with SARS-CoV-2 infection, being an accessible, cost-effective, and easy-to-use biomarker in daily clinical practice.Viruses335https://www.ebi.ac.uk/biostudies/studies/S-EPMC10976262biostudies-literaturePrognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National Cohort.PMC10976262Garcia Brunen JMRoy Vallejo EArtero Mora ASEMI-COVID-19 NetworkRamirez Perea NOblitas CMPerales-Fraile IDemelo-Rodriguez PFonseca Aizpuru EPesqueira Fontan PMAlvarez-Sala-Walther LAAroza Espinar MLopez Castro JBeato Perez JLDiez Garcia LFde Jorge-Huerta LGil Sanchez RGiner Galvan VNavarro-Romero FCasas-Rojo JMGarcia Garcia GMRubio-Rivas MMartinez Gonzalez ALMillan Nunez-Cortes JVargas Nunez JAfalsePrognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National Cohort.<h4>Background</h4>This study aimed to validate the role of the D-dimer to lymphocyte ratio (DLR) for mortality prediction in a large national cohort of hospitalized coronavirus disease 2019 (COVID-19) patients.<h4>Methods</h4>A retrospective, multicenter, observational study that included hospitalized patients due to SARS-CoV-2 infection in Spain was conducted from March 2020 to March 2022. All biomarkers and laboratory indices analyzed were measured once at admission.<h4>Results</h4>A total of 10,575 COVID-19 patients were included in this study. The mean age of participants was 66.9 (±16) years, and 58.6% (6202 patients) of them were male. The overall mortality rate was 16.3% (<i>n</i> = 1726 patients). Intensive care unit admission was needed in 10.5% (<i>n</i> = 1106 patients), non-invasive mechanical ventilation was required in 8.8% (<i>n</i> = 923 patients), and orotracheal intubation was required in 7.5% (789 patients). DLR presented a c-statistic of 0.69 (95% CI, 0.68-0.71) for in-hospital mortality with an optimal cut-off above 1. Multivariate analysis showed an independent association for in-hospital mortality for DLR > 1 (adjusted OR 2.09, 95% CI 1.09-4.04; <i>p</i> = 0.03); in the same way, survival analysis showed a higher mortality risk for DLR > 1 (HR 2.24; 95% CI 2.03-2.47; <i>p</i> < 0.01). Further, no other laboratory indices showed an independent association for mortality in multivariate analysis.<h4>Conclusions</h4>This study confirmed the usefulness of DLR as a prognostic biomarker for mortality associated with SARS-CoV-2 infection, being an accessible, cost-effective, and easy-to-use biomarker in daily clinical practice.2024-01-01T00:00:00Z2024 Feb2025-04-22T21:31:08.249Z2025-04-22T21:31:08.249ZS-EPMC109762623854370010.3390/v16030335